The initial success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies heavily reliant on unbranded versions presents a uncertain picture. Although early earnings were impressive, the end of patents and the emergence of discounted alternatives have weakened sales. Consequently, a thorough analysis o